NEW YORK (GenomeWeb) – GenMark Diagnostics said Thursday that it has applied to the US Food and Drug Administration for clearance of its ePlex Blood Culture ID – Gram Positive (BCID-GP) panel.

It is the first of three blood culture panels being developed on the ePlex molecular sample-to-answer system for the diagnosis and management of bloodstream infections that can lead to sepsis, the firm said.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.